Fasnall benzenesulfonate

Description: Fasnall, a fatty acid synthase (FASN) inhibitor, exhibits an IC50 of 3.71 µM against the human recombinant enzyme. It halts tritiated acetate incorporation into lipids (IC50= 5.84 µM), boosts ceramide levels, and triggers lipid droplet formation in BT474 HER2+ breast cancer cells. Demonstrating antiproliferative effects on various breast cancer cell lines, including non-tumorigenic MCF-10A and tumorigenic MCF-7, MDA-MB-468, BT474, and SK-BR-3, its efficacy is directly linked to FASN expression in vitro. In murine models of HER2+ breast cancer, particularly the MMTV-Neu model, Fasnall significantly reduces tumor volume and extends survival. Furthermore, it enhances the efficacy of carboplatin in vivo, bolstering the objective response rate of stable disease from 25% with carboplatin alone to 88% when paired with Fasnall. Target: Others. Smiles: S(=O)(=O)(O)C1=CC=CC=C1.N(C1=C2C(SC(C)=C2C)=NC=N1)C3CN(CC4=CC=CC=C4)CC3